Imaging of Solid Tumors Using 18F-TRX

Summary

This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors

Conditions

• Solid Tumor
• Solid Carcinoma
• Castration-Resistant Prostate Carcinoma
• Locally Advanced Clear Cell Renal Cell Carcinoma
• Metastatic Clear Cell Renal Cell Carcinoma
• Metastatic Malignant Solid Neoplasm
• Stage III Renal Cell Cancer AJCC v8
• Stage IV Renal Cell Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8
• Glioma, Malignant

Interventions

DRUG

18F-TRX

Given Intravenously (IV)

PROCEDURE

Positron Emission Tomography (PET)/Computerized tomography (CT)

Imaging procedure

PROCEDURE

Tumor Biopsy

May undergo tumor biopsy

PROCEDURE

Blood Specimen Collection

Undergo blood sample collection

Sponsors & Collaborators

• United States Department of Defense

  collaborator FED

• Rahul Aggarwal

  lead OTHER

Principal Investigators

• Rahul Aggarwal, MD · University of California, San Francisco

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-03

Primary Completion

2026-09-30

Completion

2026-09-30

FDA Drug

Yes

Countries

• United States

Study Locations